These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9404975)

  • 41. [Aprotinin in orthotopic liver transplantation].
    García Huete L; Sabaté Pes A
    Med Clin (Barc); 1997 Mar; 108(11):439. PubMed ID: 9213647
    [No Abstract]   [Full Text] [Related]  

  • 42. [Hemostasis and antifibrinolytic therapy in major pediatric surgery].
    Schindler E; Hertfelder HJ
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2013 Jul; 48(7-8):454-61; quiz 462. PubMed ID: 23929163
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacological strategies to decrease transfusion requirements in patients undergoing surgery.
    Porte RJ; Leebeek FW
    Drugs; 2002; 62(15):2193-211. PubMed ID: 12381219
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Topical use of antifibrinolytic agents reduces postoperative bleeding: a double-blind, prospective, randomized study.
    Baric D; Biocina B; Unic D; Sutlic Z; Rudez I; Vrca VB; Brkic K; Ivkovic M
    Eur J Cardiothorac Surg; 2007 Mar; 31(3):366-71; discussion 371. PubMed ID: 17218108
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [The rational use of aprotinin during orthotopic liver transplantation].
    Lagneau F; Kavafyan J; Marty J
    Ann Fr Anesth Reanim; 2001 Apr; 20(4):421-2. PubMed ID: 11392257
    [No Abstract]   [Full Text] [Related]  

  • 46. The use of thromboelastometry in the assessment of hemostasis during orthotopic liver transplantation reduces the demand for blood products.
    Trzebicki J; Flakiewicz E; Kosieradzki M; Blaszczyk B; Kołacz M; Jureczko L; Pacholczyk M; Chmura A; Lagiewska B; Lisik W; Wasiak D; Kosson D; Kwiatkowski A; Lazowski T
    Ann Transplant; 2010; 15(3):19-24. PubMed ID: 20877262
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tranexamic acid compared with high-dose aprotinin in primary elective heart operations: effects on perioperative bleeding and allogeneic transfusions.
    Casati V; Guzzon D; Oppizzi M; Bellotti F; Franco A; Gerli C; Cossolini M; Torri G; Calori G; Benussi S; Alfieri O
    J Thorac Cardiovasc Surg; 2000 Sep; 120(3):520-7. PubMed ID: 10962414
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Can we safely reduce blood loss during lumbar pedicle subtraction osteotomy procedures using tranexamic acid or aprotinin? A comparative study with controls.
    Baldus CR; Bridwell KH; Lenke LG; Okubadejo GO
    Spine (Phila Pa 1976); 2010 Jan; 35(2):235-9. PubMed ID: 20081519
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Con: Aprotinin has a good efficacy and safety profile relative to other alternatives for prevention of bleeding in cardiac surgery.
    Beattie WS; Karkouti K
    Anesth Analg; 2006 Dec; 103(6):1360-4. PubMed ID: 17122203
    [No Abstract]   [Full Text] [Related]  

  • 50. Aprotinin and nafamostat mesilate in liver surgery: effect on blood loss.
    Pereboom IT; de Boer MT; Porte RJ; Molenaar IQ
    Dig Surg; 2007; 24(4):282-7. PubMed ID: 17657153
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Effects of topical applications of aprotinin and tranexamic acid on blood loss after open heart surgery].
    Yasim A; Aşik R; Atahan E
    Anadolu Kardiyol Derg; 2005 Mar; 5(1):36-40. PubMed ID: 15755701
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The efficacy of antifibrinolytics in the reduction of blood loss during complex adult reconstructive spine surgery.
    Urban MK; Beckman J; Gordon M; Urquhart B; Boachie-Adjei O
    Spine (Phila Pa 1976); 2001 May; 26(10):1152-6. PubMed ID: 11413430
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Natural and synthetic antifibrinolytics in adult cardiac surgery: efficacy, effectiveness and efficiency.
    Hardy JF; Bélisle S
    Can J Anaesth; 1994 Nov; 41(11):1104-12. PubMed ID: 7530172
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Increased recombinant activated factor VII use and need for surgical reexploration following a switch from aprotinin to epsilon-aminocaproic acid in infant cardiac surgery.
    Scott JP; Costigan DJ; Hoffman GM; Simpson PM; Dasgupta M; Punzalan R; Berens RJ; Tweddell JS; Stuth EA
    J Clin Anesth; 2014 May; 26(3):204-11. PubMed ID: 24809789
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Local and systemic hemostasis in surgery].
    Bechstein WO; Strey C
    Chirurg; 2007 Feb; 78(2):95-6, 98-100. PubMed ID: 17237955
    [TBL] [Abstract][Full Text] [Related]  

  • 56. No increase in blood transfusions during liver transplantation since the withdrawal of aprotinin.
    Schofield N; Sugavanam A; Thompson K; Mallett SV
    Liver Transpl; 2014 May; 20(5):584-90. PubMed ID: 24481770
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The risks associated with aprotinin use: a retrospective study of cardiac cases in Nova Scotia.
    Riddell RE; Buth KJ; Sullivan JA
    Can J Anaesth; 2013 Jan; 60(1):16-23. PubMed ID: 23132043
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The use of antifibrinolytic agents in total hip arthroplasty: a meta-analysis.
    Gill JB; Rosenstein A
    J Arthroplasty; 2006 Sep; 21(6):869-73. PubMed ID: 16950041
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of blood-conservation strategies in cardiac surgery patients at high risk for bleeding.
    Nuttall GA; Oliver WC; Ereth MH; Santrach PJ; Bryant SC; Orszulak TA; Schaff HV
    Anesthesiology; 2000 Mar; 92(3):674-82. PubMed ID: 10719945
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prophylactic drug treatment in the prevention of postoperative bleeding.
    Tyers GF
    Ann Thorac Surg; 1997 Mar; 63(3):912. PubMed ID: 9066438
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.